Patents by Inventor Fumimaro Takaku
Fumimaro Takaku has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7033828Abstract: A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR?, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.Type: GrantFiled: March 1, 2001Date of Patent: April 25, 2006Assignees: The Salk Institute for Biological Studies, Sloan-Kettering Institute for Caneer ResearchInventors: Fumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald Mark Evans, Kazuhiko Umesono
-
Publication number: 20040171800Abstract: A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR&ggr;, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.Type: ApplicationFiled: March 1, 2001Publication date: September 2, 2004Applicants: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Fumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald Mark Evans, Kazuhiko Umesono
-
Publication number: 20020077457Abstract: A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR&ggr;, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.Type: ApplicationFiled: March 1, 2001Publication date: June 20, 2002Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Fumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald Mark Evans, Kazuhiko Umesono
-
Patent number: 6284870Abstract: A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR&ggr;, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.Type: GrantFiled: June 7, 1995Date of Patent: September 4, 2001Assignees: The Salk Institute for Biological Studies, Sloan-Kettering Institute for Cancer ResearchInventors: Fumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald Mark Evans, Kazuhiko Umesono
-
Patent number: 5756686Abstract: Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45 kDa endothelial cell mitogen that has been purified to homogeneity from human platelets. It does not bind to heparin and does not stimulate the proliferation of fibroblasts, in contrast to other endothelial mitogens of the fibroblast growth factor (FGF) family. PD-ECGF appears to be the only endothelial cell growth factor in human platelets and recent data indicate that it has angiogenic activity in vitro, i.e., the ability to stimulate the formation of new blood vessels and chemotactic activity, in vitro. The present invention provides a homogeneous PD-ECGF in substantially greater yields than available in the past, the primary structure of PD-ECGF, antibodies against PD-ECGF, clones of its cDNA, and variants thereof. The invention also provides a therapeutic preparation of PD-ECGF.Type: GrantFiled: November 15, 1991Date of Patent: May 26, 1998Assignee: Ludwig Institute For Cancer ResearchInventors: Carl-Henrik Heldin, Kohei Miyazono, Christer Wernstedt, Ulf Hellman, Fumimaro Takaku, Fuyuki Ishikawa
-
Patent number: 5530094Abstract: A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR.gamma., which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.Type: GrantFiled: July 30, 1993Date of Patent: June 25, 1996Assignee: The Salk Institute For Biological StudiesInventors: Fumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald M. Evans, Kazuhiko Umesono
-
Patent number: 5288487Abstract: Human M-CSF preparations and recombinant human M-CSF preparations against myelodysplastic syndrome, malignant tumor and hyperlipemia and auxiliary therapeutic preparations to be dosed along with platinum-complex anticancer preparations.Type: GrantFiled: November 6, 1991Date of Patent: February 22, 1994Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Takuji Kawashima, Nobuya Yanai, Muneo Yamada, Hajime Yokota, Kunio Ujiie, Katsuo Yoshida, Shinya Suzu, Fumimaro Takaku, Kazuo Motoyoshi, Nobuhiro Yamada
-
Patent number: 5260432Abstract: A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR.gamma., which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.Type: GrantFiled: June 22, 1989Date of Patent: November 9, 1993Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Fumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald M. Evans, Kazuhiko Umesono
-
Patent number: 5227302Abstract: Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45 kDa endothelial cell mitogen that has been purified to homogeneity from human platelets. It does not bind to heparin and does not stimulate the proliferation of fibroblasts, in contrast to other endothelial mitogens of the fibroblast growth factor (FGF) family. PD-ECGF appears to be the only endothelial cell growth factor in human platelets and recent data indicate that it has angiogenic activity in vitro, i.e., the ability to stimulate the formation of new blood vessels and chemotactic activity, in vitro. The present invention provides a homogeneous PD-ECGF in substantially greater yields than available in the past, the primary structure of PD-ECGF, antibodies against PD-ECGF, clones of its cDNA, and variants thereof. The invention also provides a therapeutic preparation of PD-ECGF.Type: GrantFiled: August 2, 1991Date of Patent: July 13, 1993Assignee: Ludwig Institute for Cancer ResearchInventors: Carl-Henrik Heldin, Kohei Miyazono, Christer Wernstedt, Ulf G. T. Hellman, Fumimaro Takaku, Fuyuki Ishikawa
-
Patent number: 5114710Abstract: A therapeutic agent for thrombocytopenia due to hemopoietic disorder induced by various causes comprises as an active ingredient a specific human monocytemacrophage colony stimulating factor. It is administered for the treatment and/or prevention of such thrombocytopenia.Type: GrantFiled: February 10, 1989Date of Patent: May 19, 1992Assignees: Green Cross Corporation, Morinaga Milk Industry Co., Ltd.Inventors: Fumimaro Takaku, Kazuo Motoyoshi
-
Patent number: 4342828Abstract: A colony stimulating factor effective in treating human granulocytopenia is produced by cultivating monocytes and macrophages isolated from the human peripheral blood in a synthetic medium for tissue culture containing a glycoprotein isolated from human urine and capable of stimulating the formation of human granulocytes or mouse macrophages and granulocytes.Type: GrantFiled: July 15, 1980Date of Patent: August 3, 1982Assignees: Morinaga Milk Industry Co., Ltd., The Green Cross Corp.Inventors: Fumimaro Takaku, Katsuhiro Ogasa, Morio Kuboyama, Nobuya Yanai, Muneo Yamada, Yoshiteru Watanabe
-
Patent number: 4275056Abstract: A colony-stimulating factor having definite physical and chemical properties and a function of stimulating activity on human bone marrow cells to proliferate and differentiate, thereby forming granulocyte colonies, is obtained from human urine by concentrating the urine with respect to proteins contained therein by adsorption chromatography with silica gel, salting out with ammonium sulfate and other means, then removing impurities by adsorption on cation exchanger, and further purifying by ion exchanging chromatography on anion exchanger, gel filtrating chromatography with highly crosslinked gels, affinitive chromatography with sugar affinitire adsorbents and electrophoresis.Type: GrantFiled: March 19, 1979Date of Patent: June 23, 1981Assignees: Morinaga Milk Industry Co., Ltd., The Green Cross CorporationInventors: Fumimaro Takaku, Katsuhiro Ogasa, Morio Kuboyama, Minoru Saito, Nobuya Yanai, Masayuki Nishida